1. Home
  2. IAUX vs ABCL Comparison

IAUX vs ABCL Comparison

Compare IAUX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i-80 Gold Corp.

IAUX

i-80 Gold Corp.

HOLD

Current Price

$1.44

Market Cap

1.3B

Sector

N/A

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$7.34

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IAUX
ABCL
Founded
2020
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
IAUX
ABCL
Price
$1.44
$7.34
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$1.50
$8.40
AVG Volume (30 Days)
10.1M
6.5M
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
10.91
EPS
N/A
N/A
Revenue
$95,193,000.00
$75,128,000.00
Revenue This Year
$132.25
N/A
Revenue Next Year
$89.76
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
89.12
160.56
52 Week Low
$0.55
$2.75
52 Week High
$2.24
$6.86

Technical Indicators

Market Signals
Indicator
IAUX
ABCL
Relative Strength Index (RSI) 43.54 70.75
Support Level $0.92 $3.32
Resistance Level $1.65 N/A
Average True Range (ATR) 0.07 0.49
MACD -0.01 0.11
Stochastic Oscillator 23.08 87.27

Price Performance

Historical Comparison
IAUX
ABCL

About IAUX i-80 Gold Corp.

i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: